biote Corp.

NASDAQ:BTMD

Medical - Care Facilities

Healthcare
$1.23 +0.22%

+$0.01 today

Market cap
$54.25M
Beta
1.66
P/E (TTM)
4.5
EPS (TTM)
$0.51
52W Low $1.27High $4.75

Volume 0.11M

Average 0.25M

BTMD Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

biote Corp.NASDAQ: BTMD

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 67.1%

Gross margin was 67.1% in Q1 FY2026, down 5.4 pp from a year earlier. On a trailing-twelve-month basis it was 68.5%, down 2.3 pp year over year. Over 3 fiscal years it widened by 2.8 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
67.1%+0.7 pp QoQ
Last fiscal yearDec 2025
69.8%-0.8 pp YoY
LTMMar 2026
68.5%-2.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-5.4 pp——
1 year-0.8 pp——
3 years+2.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
69.8%
Year-over-year change
-0.8pp

Gross Margin vs competitors

How BTMD compares with its peers on the latest reported figures

  • BTMD's LTM Mar 2026 gross margin of 68.5% is the 4th highest of the 8 companies compared; the peer median is 58.6%.
  • Its year-over-year change of -2.3 pp is the 5th highest of 7, against a peer median of +13.8 pp.
  • Over three fiscal years its change of +2.8 pp compares with a peer median of -3.9 pp.
BTMD Competitors Peer median
Gross Margin for BTMD and competitors
Company Period LTM level YoY 3-year change
INOInovio Pharmaceuticals, Inc.FY2025100.0% +0.0 pp+0.0 pp
SPROSpero Therapeutics, Inc.LTM Mar 2026100.0% +296.0 pp+0.0 pp
JYNTThe Joint Corp.LTM Mar 202679.9% +46.7 pp-11.4 pp
BTMDbiote Corp.LTM Mar 202668.5% -2.3 pp+2.8 pp
ANIKAnika Therapeutics, Inc.LTM Mar 202658.6% -4.1 pp-7.8 pp
SCLXScilex Holding CompanyLTM Mar 202655.0% -17.0 pp-21.9 pp
MCRBSeres Therapeutics, Inc.LTM Mar 2026-20.9% ——
LUCDLucid Diagnostics Inc.LTM Mar 2026-40.0% +27.6 pp+798.4 pp
VORVor Biopharma Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
ACTUActuate Therapeutics IncFY2025— ——
Peer median (excluding BTMD) 58.6%+13.8 pp-3.9 pp

Competitors are the stored peer set for BTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue139.4M164.96M185.36M197.19M192.22M
Cost of Revenue48.82M54.58M57.88M58.13M58.13M
Gross Profit90.58M110.38M127.48M139.06M134.09M
Gross Margin65.0%66.9%68.8%70.5%69.8%
Research & Development00000
Selling, General & Admin53.96M171.1M98.83M107.45M94.97M
Operating Expenses56.02M171.1M98.83M107.45M94.97M
Depreciation & Amortization1.4M2.2M794K3.57M3.67M
EBITDA35.98M7.96M39.54M15.59M53.12M
EBITDA Margin25.8%4.8%21.3%7.9%27.6%
Operating Income34.56M(60.72M)28.66M31.61M39.12M
Operating Margin24.8%-36.8%15.5%16.0%20.4%
Interest Income0000900K
Interest Expense1.67M4.05M6.36M11M11.86M
Other Income / Expenses(1.66M)62.43M(28.78M)(30.6M)(1.54M)
Income Before Tax32.91M1.71M(123K)1.02M37.58M
Pre-Tax Margin23.6%1.0%-0.1%0.5%19.6%
Income Tax Expense286K388K2.68M970K5.99M
Net Income32.62M(969K)3.32M3.16M27.05M
Net Margin23.4%-0.6%1.8%1.6%14.1%
EPS (Basic)(0.87)0.160.130.090.86
EPS (Diluted)(0.87)0.160.130.090.74
Weighted Avg Shares7.57M8.06M25.71M34.27M31.28M
Weighted Avg Shares (Diluted)7.57M8.06M25.71M34.27M36.67M

biote Corp.

NASDAQ:BTMD

Intrinsic Alpha fair value

Locked

Current Price

$1.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.